James Mwanza
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
James Mwanza has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Brian Chanda Chiluba
The University of Zambia, School of Health Sciences
2 shared publications Charity Kapenda
¹The University of Zambia, School of Health Sciences, Department of Physiotherapy
2 shared publications- Nchawanangwa Kaonga
¹The University of Zambia, School of Health Sciences, Department of Physiotherapy
2 shared publications - Alian Aa Alrasheedy
Department of Pharmacy Practice, College of Pharmacy, Qassim University, Qassim 51452, Saudi Arabia
1 shared publication Amos Massele
Department of Biomedical Sciences, Faculty of Medicine, University of Botswana, Gaborone, Botswana
1 shared publication- Antony Paul Martin
QC Medica, Liverpool, UK
1 shared publication
Latest Publications
- 1 June 2021
- Published by School of Health Sciences, Department of Physiotherapy, University of Zambia in Journal of Preventive and Rehabilitative Medicine
- Vol. 3 (2) , 24-31
Trends of Anticholinergics and Antipsychotics Prescribing at Chainama Hills College Hospital, Lusaka-Zambia
Introduction:Antipsychotics are the main pharmacological treatment for psychosis. Anticholinergic drugs are sometimes prescribed with antipsychotics to treat or as prophylaxis for extrapyramidal side effects. Antipsychotic treatment guidelines recommend that anticholinergics should not be prescribed indiscriminately as prophylaxis for extrapyramidal side effects to patients using antipsychotic drugs, but only when there is high risk or evidence of extrapyramidal side effects, as they can cause significant central and peripheral side effects which have a potential to affect treatment outcomes. The objective of the study was to assess the trends in the prescribing of antipsychotics and anticholinergics.Methods:A cross sectional study was conducted at Chainama Hills College Hospital in Zambia. An open-ended questionnaire was administered to 26 prescribers and 311 files for patients were reviewed who had an antipsychotic or anticholinergic drug prescribed. The prescription pattern of patient files was compared with theNational Institute for Health and Care Excellenceguidelines as a gold standard.Results:The antipsychotic distribution showed that 76.1% were prescribed a typical antipsychotic, 18.1% an atypical antipsychotic and 5.8% were on both typical and atypical antipsychotic. 28.2% of the patients on antipsychotics were prescribed anticholinergics (Trihexyphenidyl). 46.2% of the prescribing clinicians stated that they prescribe anticholinergics when a patient develops extrapyramidal side effects rather than concurrently with antipsychotics or when a high dose of antipsychotics has been prescribed.Conclusion:The trend in antipsychotic and anticholinergic prescribing in Lusaka-Zambia were not consistent with recommended guidelines. Majority of patients are on typical antipsychotics rather than atypical antipsychotics. Most patients were administered above optimal dose of antipsychotics though polypharmacy was solemnly practiced. Recommend that further studies to explore factors contributing to this trend are conducted.
- 1 June 2021
- Published by School of Health Sciences, Department of Physiotherapy, University of Zambia in Journal of Preventive and Rehabilitative Medicine
- Vol. 3 (2) , 24-31
Trends of Anticholinergics and Antipsychotics Prescribing at Chainama Hills College Hospital, Lusaka-Zambia
Introduction:Antipsychotics are the main pharmacological treatment for psychosis. Anticholinergic drugs are sometimes prescribed with antipsychotics to treat or as prophylaxis for extrapyramidal side effects. Antipsychotic treatment guidelines recommend that anticholinergics should not be prescribed indiscriminately as prophylaxis for extrapyramidal side effects to patients using antipsychotic drugs, but only when there is high risk or evidence of extrapyramidal side effects, as they can cause significant central and peripheral side effects which have a potential to affect treatment outcomes. The objective of the study was to assess the trends in the prescribing of antipsychotics and anticholinergics.Methods:A cross sectional study was conducted at Chainama Hills College Hospital in Zambia. An open-ended questionnaire was administered to 26 prescribers and 311 files for patients were reviewed who had an antipsychotic or anticholinergic drug prescribed. The prescription pattern of patient files was compared with theNational Institute for Health and Care Excellenceguidelines as a gold standard.Results:The antipsychotic distribution showed that 76.1% were prescribed a typical antipsychotic, 18.1% an atypical antipsychotic and 5.8% were on both typical and atypical antipsychotic. 28.2% of the patients on antipsychotics were prescribed anticholinergics (Trihexyphenidyl). 46.2% of the prescribing clinicians stated that they prescribe anticholinergics when a patient develops extrapyramidal side effects rather than concurrently with antipsychotics or when a high dose of antipsychotics has been prescribed.Conclusion:The trend in antipsychotic and anticholinergic prescribing in Lusaka-Zambia were not consistent with recommended guidelines. Majority of patients are on typical antipsychotics rather than atypical antipsychotics. Most patients were administered above optimal dose of antipsychotics though polypharmacy was solemnly practiced. Recommend that further studies to explore factors contributing to this trend are conducted.
- Open Access
- 1 June 2021
- Published by School of Health Sciences, Department of Physiotherapy, University of Zambia in Journal of Preventive and Rehabilitative Medicine
- Vol. 3 (2) , 42-55
A Crossover Design for Comparative Efficacy: A 28 Days-Randomized Clinical Trial of Cognitive Behavioral Therapy for Chronic Pain of Degenerative Conditions
In physiotherapy practice, a number of patients are known to suffer from chronic pain which results in reduced activity levels, interference in sleep, enjoyment of life, mood, and relations with others. Cognitive behavioral therapy, in this aspect will provide a holistic approach to the available treatment. Cognitive behavioral therapy has also been shown to target cognitive distortions such as pain catastrophizing, fear avoidance, overgeneralizing and others, all the while improving physical health, activity levels and quality of life. This study assessed the efficacy of cognitive behavioral therapy in the management of patients with chronic pain at the University Teaching Hospitals in Zambia. A randomized clinical trial utilizing a crossover design was utilized for the study. A random sample of 32 participants was used in the study after fulfilling the study criteria. Data was analyzed using ANCOVA with alpha of 0.05. The study recorded small effects in the reduction of pain intensity in both phase one and two. In phase one, it also recorded small effects in general work interference, sleep interference and enjoyment of life interference but recorded medium effects in normal work interference and mood interference. Phase two of the study recorded small effect size in reduction of general work interference, normal work interference, mood interference, relations with others interference, sleep interference and Enjoyment of Life interference. Cognitive behavioral therapy ensures the management of chronic pain addresses areas in which an individual is affected by pain and which in turn exacerbate the chronic pain. Physiotherapy provides a more holistic approach when used in conjunction with cognitive behavioral therapy.
- 1 June 2021
- Published by School of Health Sciences, Department of Physiotherapy, University of Zambia in Journal of Preventive and Rehabilitative Medicine
- Vol. 3 (2) , 42-55
Open AccessA Crossover Design for Comparative Efficacy: A 28 Days-Randomized Clinical Trial of Cognitive Behavioral Therapy for Chronic Pain of Degenerative Conditions
In physiotherapy practice, a number of patients are known to suffer from chronic pain which results in reduced activity levels, interference in sleep, enjoyment of life, mood, and relations with others. Cognitive behavioral therapy, in this aspect will provide a holistic approach to the available treatment. Cognitive behavioral therapy has also been shown to target cognitive distortions such as pain catastrophizing, fear avoidance, overgeneralizing and others, all the while improving physical health, activity levels and quality of life. This study assessed the efficacy of cognitive behavioral therapy in the management of patients with chronic pain at the University Teaching Hospitals in Zambia. A randomized clinical trial utilizing a crossover design was utilized for the study. A random sample of 32 participants was used in the study after fulfilling the study criteria. Data was analyzed using ANCOVA with alpha of 0.05. The study recorded small effects in the reduction of pain intensity in both phase one and two. In phase one, it also recorded small effects in general work interference, sleep interference and enjoyment of life interference but recorded medium effects in normal work interference and mood interference. Phase two of the study recorded small effect size in reduction of general work interference, normal work interference, mood interference, relations with others interference, sleep interference and Enjoyment of Life interference. Cognitive behavioral therapy ensures the management of chronic pain addresses areas in which an individual is affected by pain and which in turn exacerbate the chronic pain. Physiotherapy provides a more holistic approach when used in conjunction with cognitive behavioral therapy.
- Open Access
- 1 October 2020
- Published by School of Health Sciences, Department of Physiotherapy, University of Zambia in Journal of Preventive and Rehabilitative Medicine
- Vol. 2 (1) , 27-31
Efficacy of Cognitive Behavioral Therapy in Managing Chronic Pain of Degenerative Conditions: An Overview of Randomized Clinical Trials and Meta-Analysis Studies
Background:Cognitive behavioral therapy is a goal-oriented psychotherapy treatment that takes a hands-on, practical approach to problem-solving. It has been documented in various studies to have an impact when used in the management of chronic pain. It has been shown to lack the drawbacks of pharmacological and surgical treatments such as addiction and toxicity; and cost and recovery time, respectively. Cognitive behavioral therapy has also been shown to target cognitive distortions such as pain catastrophizing among other things. The objective of the review is to evaluate the effectiveness of cognitive behavioral therapy in the management of chronic pain of degenerative conditions. Methods:This review article was conducted basing on the previous studies published from 2009-2019 and data analyzed was retrieved from Google Scholar, Elsevier and Science Direct. Only the articles that looked at effectiveness of cognitive behavioral therapy in the management of chronic pain from a physiotherapists point were included. Results:The outcomes of the studies used varied and included reduction in pain intensity, pain disability, fear avoidance, catastrophizing and kinesophobia. The CBT approaches used across the studies also varied and included operant conditioning, biofeedback, relaxation techniques, pacing, cognitive coping techniques, graded activity and graded exposure.Conclusion:Published randomized controlled trials provide good evidence for the effectiveness of cognitive behavioral therapy and how specific approaches may vary in effectiveness depending on the desired outcomes
- 1 October 2020
- Published by School of Health Sciences, Department of Physiotherapy, University of Zambia in Journal of Preventive and Rehabilitative Medicine
- Vol. 2 (1) , 27-31
Open AccessEfficacy of Cognitive Behavioral Therapy in Managing Chronic Pain of Degenerative Conditions: An Overview of Randomized Clinical Trials and Meta-Analysis Studies
Background:Cognitive behavioral therapy is a goal-oriented psychotherapy treatment that takes a hands-on, practical approach to problem-solving. It has been documented in various studies to have an impact when used in the management of chronic pain. It has been shown to lack the drawbacks of pharmacological and surgical treatments such as addiction and toxicity; and cost and recovery time, respectively. Cognitive behavioral therapy has also been shown to target cognitive distortions such as pain catastrophizing among other things. The objective of the review is to evaluate the effectiveness of cognitive behavioral therapy in the management of chronic pain of degenerative conditions. Methods:This review article was conducted basing on the previous studies published from 2009-2019 and data analyzed was retrieved from Google Scholar, Elsevier and Science Direct. Only the articles that looked at effectiveness of cognitive behavioral therapy in the management of chronic pain from a physiotherapists point were included. Results:The outcomes of the studies used varied and included reduction in pain intensity, pain disability, fear avoidance, catastrophizing and kinesophobia. The CBT approaches used across the studies also varied and included operant conditioning, biofeedback, relaxation techniques, pacing, cognitive coping techniques, graded activity and graded exposure.Conclusion:Published randomized controlled trials provide good evidence for the effectiveness of cognitive behavioral therapy and how specific approaches may vary in effectiveness depending on the desired outcomes
- Open Access
- 25 November 2019
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- Vol. 20 (18) , 2237-2255
Pharmacotherapeutic interventions for bipolar disorder type II: addressing multiple symptoms and approaches with a particular emphasis on strategies in lower and middle-income countries
Introduction: Appropriately managing mental disorders is a growing priority across countries in view of the impact on morbidity and mortality. This includes patients with bipolar disorders (BD). Management of BD is a concern as this is a complex disease with often misdiagnosis, which is a major issue in lower and middle-income countries (LMICs) with typically a limited number of trained personnel and resources. This needs to be addressed. Areas covered: Medicines are the cornerstone of managing patients with Bipolar II across countries including LMICs. The choice of medicines, especially antipsychotics, is important in LMICs with high rates of diabetes and HIV. However, care is currently compromised in LMICs by issues such as the stigma, cultural beliefs, a limited number of trained professionals and high patient co-payments. Expert opinion: Encouragingly, some LMICs have introduced guidelines for patients with BD; however, this is very variable. Strategies for the future include addressing the lack of national guidelines for patients with BD, improving resources for mental disorders including personnel, improving medicine availability and patients’ rights, and monitoring prescribing against agreed guidelines. A number of strategies have been identified to improve the treatment of patients with Bipolar II in LMICs, and will be followed up.
- 25 November 2019
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- Vol. 20 (18) , 2237-2255
Open AccessPharmacotherapeutic interventions for bipolar disorder type II: addressing multiple symptoms and approaches with a particular emphasis on strategies in lower and middle-income countries
Introduction: Appropriately managing mental disorders is a growing priority across countries in view of the impact on morbidity and mortality. This includes patients with bipolar disorders (BD). Management of BD is a concern as this is a complex disease with often misdiagnosis, which is a major issue in lower and middle-income countries (LMICs) with typically a limited number of trained personnel and resources. This needs to be addressed. Areas covered: Medicines are the cornerstone of managing patients with Bipolar II across countries including LMICs. The choice of medicines, especially antipsychotics, is important in LMICs with high rates of diabetes and HIV. However, care is currently compromised in LMICs by issues such as the stigma, cultural beliefs, a limited number of trained professionals and high patient co-payments. Expert opinion: Encouragingly, some LMICs have introduced guidelines for patients with BD; however, this is very variable. Strategies for the future include addressing the lack of national guidelines for patients with BD, improving resources for mental disorders including personnel, improving medicine availability and patients’ rights, and monitoring prescribing against agreed guidelines. A number of strategies have been identified to improve the treatment of patients with Bipolar II in LMICs, and will be followed up.